Essec\Faculty\Model\Contribution {#2216 ▼
#_index: "academ_contributions"
#_id: "10228"
#_source: array:26 [
"id" => "10228"
"slug" => "10228-therapeutic-non-adherence-a-rational-behaviour-revealing-patient-preferences"
"yearMonth" => "2007-11"
"year" => "2007"
"title" => "Therapeutic non adherence: a rational behaviour revealing patient preferences?"
"description" => "LAMIRAUD, K. et GEOFFARD, P.Y. (2007). Therapeutic non adherence: a rational behaviour revealing patient preferences? <i>Health Economics</i>, 16(11), pp. 1185-1204. 
LAMIRAUD, K. et GEOFFARD, P.Y. (2007). Therapeutic non adherence: a rational behaviour revealing pat "
"authors" => array:2 [
0 => array:3 [
"name" => "LAMIRAUD Karine"
"bid" => "B00278040"
"slug" => "lamiraud-karine"
]
1 => array:1 [
"name" => "GEOFFARD Pierre-Yves"
]
]
"ouvrage" => ""
"keywords" => array:5 [
0 => "drug valuation method"
1 => "revealed preferences"
2 => "endogenous adherence behavior"
3 => """
panel bivariate probit\n
estimation
"""
4 => """
HIV\n
INTRODUCTION
"""
]
"updatedAt" => "2021-07-13 14:31:30"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "1185-1204"
"volume" => "16"
"number" => "11"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
This paper offers an indirect measure of patient welfare based on whether patients comply with the prescription they\n This paper offers an indirect measure of patient welfare based on whether patients comply with the p
receive. Adherence behavior is supposed to reveal patients¿ subjective valuations of particular therapies. We write a\n receive. Adherence behavior is supposed to reveal patients¿ subjective valuations of particular ther
simple theoretical model of patient adherence behavior, that reflects the trade-off between perceived costs and\n simple theoretical model of patient adherence behavior, that reflects the trade-off between perceive
observed regimen efficacy. A discrete choice framework is then used for the estimation, i.e. the comparison of the\n observed regimen efficacy. A discrete choice framework is then used for the estimation, i.e. the com
incremental benefit of drug intake between two regimens. Consequently, the empirical analysis is based on the\n incremental benefit of drug intake between two regimens. Consequently, the empirical analysis is bas
identification of patient and drug characteristics associated with adherence. The econometric approach is\n identification of patient and drug characteristics associated with adherence. The econometric approa
implemented through a bivariate panel two-equation simultaneous system studying jointly the factors associated\n implemented through a bivariate panel two-equation simultaneous system studying jointly the factors
with adherence and response to treatment. The data come from a randomized clinical trial conducted in France\n with adherence and response to treatment. The data come from a randomized clinical trial conducted i
between 1999 and 2001 and comparing the efficacy of two tritherapy strategies in HIV disease.\n
Both the theoretical and empirical results suggest that, for comparable clinical efficacy and toxicity levels, a\n Both the theoretical and empirical results suggest that, for comparable clinical efficacy and toxici
higher adherence level is associated with higher patient welfare, thus adding valuable information to conclusions\n higher adherence level is associated with higher patient welfare, thus adding valuable information t
drawn by a mere biostatistical analysis. Therefore, from the perspective of the patient, the adherence-enhancing\n drawn by a mere biostatistical analysis. Therefore, from the perspective of the patient, the adheren
drug must be favored. Our results based on panel data also stress that unobserved patient characteristics account\n drug must be favored. Our results based on panel data also stress that unobserved patient characteri
substantially for drug valuation and that the assessment evolves during the course of the treatment. Furthermore,\n substantially for drug valuation and that the assessment evolves during the course of the treatment.
we provide a new framework for the analysis of adherence data. The microeconometric framework highlights that\n we provide a new framework for the analysis of adherence data. The microeconometric framework highli
non-adherence is an endogenous behavior, thus suggesting new ways for improving adherence
"""
"en" => """
This paper offers an indirect measure of patient welfare based on whether patients comply with the prescription they\n This paper offers an indirect measure of patient welfare based on whether patients comply with the p
receive. Adherence behavior is supposed to reveal patients¿ subjective valuations of particular therapies. We write a\n receive. Adherence behavior is supposed to reveal patients¿ subjective valuations of particular ther
simple theoretical model of patient adherence behavior, that reflects the trade-off between perceived costs and\n simple theoretical model of patient adherence behavior, that reflects the trade-off between perceive
observed regimen efficacy. A discrete choice framework is then used for the estimation, i.e. the comparison of the\n observed regimen efficacy. A discrete choice framework is then used for the estimation, i.e. the com
incremental benefit of drug intake between two regimens. Consequently, the empirical analysis is based on the\n incremental benefit of drug intake between two regimens. Consequently, the empirical analysis is bas
identification of patient and drug characteristics associated with adherence. The econometric approach is\n identification of patient and drug characteristics associated with adherence. The econometric approa
implemented through a bivariate panel two-equation simultaneous system studying jointly the factors associated\n implemented through a bivariate panel two-equation simultaneous system studying jointly the factors
with adherence and response to treatment. The data come from a randomized clinical trial conducted in France\n with adherence and response to treatment. The data come from a randomized clinical trial conducted i
between 1999 and 2001 and comparing the efficacy of two tritherapy strategies in HIV disease.\n
Both the theoretical and empirical results suggest that, for comparable clinical efficacy and toxicity levels, a\n Both the theoretical and empirical results suggest that, for comparable clinical efficacy and toxici
higher adherence level is associated with higher patient welfare, thus adding valuable information to conclusions\n higher adherence level is associated with higher patient welfare, thus adding valuable information t
drawn by a mere biostatistical analysis. Therefore, from the perspective of the patient, the adherence-enhancing\n drawn by a mere biostatistical analysis. Therefore, from the perspective of the patient, the adheren
drug must be favored. Our results based on panel data also stress that unobserved patient characteristics account\n drug must be favored. Our results based on panel data also stress that unobserved patient characteri
substantially for drug valuation and that the assessment evolves during the course of the treatment. Furthermore,\n substantially for drug valuation and that the assessment evolves during the course of the treatment.
we provide a new framework for the analysis of adherence data. The microeconometric framework highlights that\n we provide a new framework for the analysis of adherence data. The microeconometric framework highli
non-adherence is an endogenous behavior, thus suggesting new ways for improving adherence
"""
]
"authors_fields" => array:2 [
"fr" => "Economie"
"en" => "Economics"
]
"indexedAt" => "2025-03-18T02:21:46.000Z"
"docTitle" => "Therapeutic non adherence: a rational behaviour revealing patient preferences?"
"docSurtitle" => "Journal articles"
"authorNames" => "<a href="/cv/lamiraud-karine">LAMIRAUD Karine</a>, GEOFFARD Pierre-Yves"
"docDescription" => "<span class="document-property-authors">LAMIRAUD Karine, GEOFFARD Pierre-Yves</span><br><span class="document-property-authors_fields">Economics</span> | <span class="document-property-year">2007</span> <span class="document-property-authors">LAMIRAUD Karine, GEOFFARD Pierre-Yves</span><br><span class= "
"keywordList" => """
<a href="#">drug valuation method</a>, <a href="#">revealed preferences</a>, <a href="#">endogenous adherence behavior</a>, <a href="#">panel bivariate probit\n <a href="#">drug valuation method</a>, <a href="#">revealed preferences</a>, <a href="#">endogenous
estimation</a>, <a href="#">HIV\n
INTRODUCTION</a>
"""
"docPreview" => "<b>Therapeutic non adherence: a rational behaviour revealing patient preferences?</b><br><span>2007-11 | Journal articles </span> <b>Therapeutic non adherence: a rational behaviour revealing patient preferences?</b><br><span>2007- "
"docType" => "research"
"publicationLink" => "<a href="#" target="_blank">Therapeutic non adherence: a rational behaviour revealing patient preferences?</a> <a href="#" target="_blank">Therapeutic non adherence: a rational behaviour revealing patient prefer "
]
+lang: "en"
+"_type": "_doc"
+"_score": 8.639269
+"parent": null
}
